Literature DB >> 30429078

Social cognitive group treatment for impaired insight in psychosis: A multicenter randomized controlled trial.

G H M Pijnenborg1, A E de Vos2, M E Timmerman3, M Van der Gaag4, B E Sportel2, J Arends2, E M Koopmans5, L Van der Meer6, A Aleman7.   

Abstract

PURPOSE: The majority of people with schizophrenia has impaired insight, which is related to a poorer outcome. In this study, we evaluate a new psychosocial intervention 'REFLEX' aimed at improving insight in people with schizophrenia. REFLEX focuses on targeting stigma-sensitivity, perspective taking and self-reflection in people with schizophrenia and low insight. Primary objective is to improve insight and subsequently to improve functional outcome and symptoms.
METHOD: A total of 121 people diagnosed with schizophrenia according to DSM IV criteria with impaired insight was included in 2012-2015 from seven sites in a multicenter randomized controlled trial. REFLEX was compared to an active control condition consisting of group-wise simplified cognitive remediation training. Primary outcome of the study were the preconditions of insight: internalized stigma, self-reflection, mental flexibility and perspective taking. Clinical insight and cognitive insight were secondary outcomes.
RESULTS: Although perspective taking, self-reflection, mental flexibility and stigma sensitivity remained unchanged after the intervention, results showed a significant improvement of clinical insight in both conditions directly after treatment (SAI-E Rater, p < .001, PANSS G12, p < .005) and at follow-up (SAI-E Rater, p < .01, SAI-E interview, p < .001, PANSS G12, p < .0001). Improvement of clinical insight directly after treatment was larger in the REFLEX condition (SAI-E Rater, p < .05). Other outcomes (self-esteem, quality of life and depression) remained unchanged.
CONCLUSION: Though insight improved in both conditions, REFLEX was not superior to simplified drill-and-practice cognitive remediation training. Nevertheless, this study indicates that structured interventions can significantly improve insight. Further research on the underlying mechanisms of both conditions is needed, as insight is unlikely to improve spontaneously in chronic patients.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Awareness; Clinical trial; Perspective taking; Schizophrenia; Self-reflection; Self-stigma

Mesh:

Year:  2018        PMID: 30429078     DOI: 10.1016/j.schres.2018.10.018

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  5 in total

Review 1.  Cognitive behavioural therapy (group) for schizophrenia.

Authors:  Giuseppe Guaiana; Massimiliano Abbatecola; Ghazaleh Aali; Federica Tarantino; Ikenna D Ebuenyi; Valeria Lucarini; Wei Li; Caidi Zhang; Antonio Pinto
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

Review 2.  Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia.

Authors:  Christine Le; Elizabeth Finger
Journal:  CNS Drugs       Date:  2021-08-24       Impact factor: 5.749

3.  Brain function differences in drug-naïve first-episode auditory verbal hallucination-schizophrenia patients with versus without insight.

Authors:  Min Chen; Chuan-Jun Zhuo; Feng Ji; Gong-Ying Li; Xiao-Yan Ke
Journal:  Chin Med J (Engl)       Date:  2019-09-20       Impact factor: 2.628

4.  Study protocol of a randomised clinical trial testing whether metacognitive training can improve insight and clinical outcomes in schizophrenia.

Authors:  Javier-David Lopez-Morinigo; Verónica González Ruiz-Ruano; Adela Sánchez Escribano Martínez; María Luisa Barrigón Estévez; Laura Mata-Iturralde; Laura Muñoz-Lorenzo; Sergio Sánchez-Alonso; Antonio Artés-Rodríguez; Anthony S David; Enrique Baca-García
Journal:  BMC Psychiatry       Date:  2020-01-29       Impact factor: 3.630

5.  Can metacognitive interventions improve insight in schizophrenia spectrum disorders? A systematic review and meta-analysis.

Authors:  Javier-David Lopez-Morinigo; Olesya Ajnakina; Adela Sánchez-Escribano Martínez; Paula-Jhoana Escobedo-Aedo; Verónica González Ruiz-Ruano; Sergio Sánchez-Alonso; Laura Mata-Iturralde; Laura Muñoz-Lorenzo; Susana Ochoa; Enrique Baca-García; Anthony S David
Journal:  Psychol Med       Date:  2020-10-14       Impact factor: 7.723

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.